(19)
(11) EP 3 039 136 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.12.2020 Bulletin 2020/51

(45) Mention of the grant of the patent:
04.11.2020 Bulletin 2020/45

(21) Application number: 14840079.9

(22) Date of filing: 28.08.2014
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
C12N 15/01(2006.01)
A61P 35/00(2006.01)
 C12N 15/90(2006.01)
A61P 31/00(2006.01)
A61P 43/00(2006.01)
(86) International application number:
PCT/US2014/053170
(87) International publication number:
WO 2015/031619 (05.03.2015 Gazette 2015/09)

(54)

COMPOSITIONS FOR LINKING DNA-BINDING DOMAINS AND CLEAVAGE DOMAINS

ZUSAMMENSETZUNGEN ZUR VERNETZUNG VON DNA-BINDUNGSDOMÄNEN UND -SPALTUNGSDOMÄNEN

COMPOSITIONS DE LIAISON DE DOMAINES DE LIAISON À L'ADN ET DE DOMAINES DE CLIVAGE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.08.2013 US 201361871219 P

(43) Date of publication of application:
06.07.2016 Bulletin 2016/27

(60) Divisional application:
19189811.3 / 3591045

(73) Proprietor: Sangamo Therapeutics, Inc.
Brisbane, CA 94005 (US)

(72) Inventors:
  • PASCHON, David
    Richmond, California 94804 (US)
  • ZHANG, Lei
    Richmond, California 94804 (US)

(74) Representative: Weickmann & Weickmann PartmbB 
Postfach 860 820
81635 München
81635 München (DE)


(56) References cited: : 
WO-A2-2014/036219
US-A1- 2008 182 332
US-A1- 2011 201 118
US-B2- 8 106 255
 US-A1- 2005 064 474
US-A1- 2009 305 419
US-A1- 2012 297 495
   
  • HÄNDEL EVA-MARIA ET AL: "Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 17, no. 1, 1 January 2009 (2009-01-01), pages 104-111, XP002551960, ISSN: 1525-0024, DOI: 10.1038/MT.2008.233
  • KIMBERLY A WILSON ET AL: "Expanding the Repertoire of Target Sites for Zinc Finger Nuclease-mediated Genome Modification", MOLECULAR THERAPY - NUCLEIC ACIDS, vol. 2, no. 4, 1 April 2013 (2013-04-01), page e88, XP055329625, DOI: 10.1038/mtna.2013.13
  • BIBIKOVA M ET AL: "Stimulation of homologous recombination through targeted cleavage by chimeric nucleases", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 21, no. 1, 1 January 2001 (2001-01-01), pages 289-297, XP002974229, ISSN: 0270-7306, DOI: 10.1128/MCB.21.1.289-297.2001
  • JOHN P GUILINGER ET AL: "Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification", NATURE BIOTECHNOLOGY, vol. 32, no. 6, 25 April 2014 (2014-04-25) , pages 577-582, XP055157221, US ISSN: 1087-0156, DOI: 10.1038/nbt.2909
  • MILLER JEFFREY C ET AL: "A TALE nuclease architecture for efficient genome editing", 1 February 2011 (2011-02-01), MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, XP002685825,
  • SMITH J ET AL: "Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains", 1 January 2000 (2000-01-01), NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, PAGE(S) 3361 - 3369, XP002974228, ISSN: 0305-1048
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).